ARWR * logo

Arrowhead Pharmaceuticals BMV:ARWR * Stock Report

Last Price

Mex$586.00

Market Cap

Mex$50.9b

7D

0%

1Y

-58.1%

Updated

17 Oct, 2023

Data

Company Financials +

Arrowhead Pharmaceuticals, Inc.

BMV:ARWR * Stock Report

Market Cap: Mex$50.9b

ARWR * Stock Overview

Develops medicines for the treatment of intractable diseases in the United States. More details

ARWR * fundamental analysis
Snowflake Score
Valuation1/6
Future Growth2/6
Past Performance0/6
Financial Health5/6
Dividends0/6

Arrowhead Pharmaceuticals, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Arrowhead Pharmaceuticals
Historical stock prices
Current Share PriceUS$586.00
52 Week HighUS$619.39
52 Week LowUS$583.00
Beta0.87
11 Month Change0%
3 Month Change0.51%
1 Year Change-58.11%
33 Year Change-45.03%
5 Year Changen/a
Change since IPO-41.61%

Recent News & Updates

Recent updates

Shareholder Returns

ARWR *MX BiotechsMX Market
7D0%0%0%
1Y-58.1%0%0%

Return vs Industry: ARWR * underperformed the MX Biotechs industry which returned -6% over the past year.

Return vs Market: ARWR * underperformed the MX Market which returned 3.7% over the past year.

Price Volatility

Is ARWR *'s price volatile compared to industry and market?
ARWR * volatility
ARWR * Average Weekly Movementn/a
Biotechs Industry Average Movement0%
Market Average Movement0%
10% most volatile stocks in MX Market0%
10% least volatile stocks in MX Market0%

Stable Share Price: ARWR * has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine ARWR *'s volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
2003397Chris Anzalonearrowheadpharma.com

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company’s products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in phase 2b clinical trial for the treatment of dyslipidemia; ARO-HSD, which is completed phase 1/2 clinical trial to treat liver diseases; ARO-ENaC2, which is in pre-clinical stage for the treatment of dyslipidemia cystic fibrosis; ARO-C3 that is in phase 1/2a clinical trial to reduce production of complement component 3; ARO-DUX4, which is in pre-clinical stage for the treatment of facioscapulohumeral muscular dystrophy; ARO-XDH that is in phase 1 clinical trial to treat uncontrolled gout; ARO-COV, which is in pre-clinical stage for the treatment of COVID-19; ARO-RAGE, which is in phase 1/2a clinical trial to treat muco-obstructive or inflammatory pulmonary conditions; and ARO-MMP7 that is in phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis. It is also involved in the development of JNJ-3989, a subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; Olpasiran to reduce the production of apolipoprotein A; and ARO-AMG1 for treating genetically validated cardiovascular targets.

Arrowhead Pharmaceuticals, Inc. Fundamentals Summary

How do Arrowhead Pharmaceuticals's earnings and revenue compare to its market cap?
ARWR * fundamental statistics
Market capMex$50.88b
Earnings (TTM)-Mex$3.24b
Revenue (TTM)Mex$4.59b

11.1x

P/S Ratio

-15.7x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ARWR * income statement (TTM)
RevenueUS$256.21m
Cost of RevenueUS$0
Gross ProfitUS$256.21m
Other ExpensesUS$437.32m
Earnings-US$181.11m

Last Reported Earnings

Jun 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-1.69
Gross Margin100.00%
Net Profit Margin-70.69%
Debt/Equity Ratio68.9%

How did ARWR * perform over the long term?

See historical performance and comparison